Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
NCT02870244
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
18
Enrollment
OTHER
Sponsor class
Conditions
Melanoma
Interventions
BIOLOGICAL:
Escalating Doses
Sponsor
Loyola University
Collaborators
[object Object]